Biodesix Extends Lung Franchise with Acquisition of Integrated Diagnostics

-Acquired assets include the XL2 blood-based test designed to improve lung cancer diagnosis–

 
BOULDER, Colo., July 9, 2018 – Biodesix, Inc., a molecular diagnostics company, announced today that the company has acquired Seattle-based Integrated Diagnostics, Inc. (Indi). The agreement includes the XL2 test, Indi’s lead oncology product, which offers a noninvasive means of ruling out cancer for patients with suspicious lung nodules. Financial terms of the deal were not disclosed.
 
Every year, health care providers in the United States discover more than 1.6 million lung nodules in patients. A significant portion of these patients will need a tissue sample extracted from the nodule to determine whether it is malignant or benign. This process is often challenging and costly, as well as invasive to the patient. The XL2 test, which requires a simple blood draw, is a pulmonary nodule classifier that measures proteins to identify lung nodules that have a high probability of being benign.
 
“The team at Indi has developed and substantially validated an important test that helps physicians better manage patients who present with a suspicious nodule in their lung,” said David Brunel, chief executive officer of Biodesix. “Adding XL2 to our portfolio demonstrates our commitment to helping physicians and patients battle lung disease across a continuum of clinical presentations.”
 
The Biodesix VeriStrat® proteomic test provides objective prognostic information independent of treatment choice, including immunotherapy. The GeneStrat® genomic test measures actionable mutations for non-small cell lung cancer to further inform therapeutic decisions and monitoring.
 
“XL2 is a perfect complement to our existing commercial blood-based lung cancer tests, which make use of advanced proteomic and genomic technology to support more informed treatment decisions,” said Scott Hutton, chief operating officer of Biodesix.
 
“We’ve been actively exploring the optimal path to bring XL2 to the market since 2017, when we validated our test,” said Al Luderer, Ph.D., chief executive officer of Integrated Diagnostics. “Indi and Biodesix share important values and technologic synergies that make this an ideal combination, including a singular focus on providing high-value, blood-based diagnostic products for lung disease and the expert application of advanced mass spectrometry and informatics. Additionally, we are impressed by Biodesix’s rapidly expanding commercial presence and extensive lung disease product pipeline.”